Welcome to our dedicated page for Nexalin Technology Warrant news (Ticker: NXLIW), a resource for investors and traders seeking the latest updates and insights on Nexalin Technology Warrant stock.
Nexalin Technology Inc. offers a drug-free therapy for anxiety, depression, and insomnia. The patented waveform of the Nexalin device provides transcranial electrical stimulation, resulting in increased beta-endorphins and balance in the brain's neurochemistry.
The FDA-approved Gen-1 device uses bioelectronic medical technology to treat anxiety and insomnia without drugs. Nexalin's neurostimulation products aim to combat the global mental health epidemic with safe and effective solutions.
The company's innovative Gen-3 HALO™ Clarity Virtual Clinic model and growing clinical data support the efficacy of its therapy. With extensive safety analysis and FDA approval, Nexalin is a leader in non-invasive mental health treatment.
Rhea-AI Summary
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Rule 5550(a)(2). CEO Mark White expresses commitment to revolutionizing mental health treatment through neurostimulation technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Nexalin Technology, Inc. (NXL) reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model. The company's CEO, Mark White, highlights positive clinical results, the introduction of HALO™ Clarity & Virtual Clinic, targeting the U.S. Government market, global market expansion, strengthening IP portfolio, and a bright future for Nexalin and mental health care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Nexalin Technology, Inc. completes successful testing for its new Gen-3 HALO™ Clarity neurostimulation device, ramping up manufacturing for upcoming clinical trials. The device offers remote treatment capabilities, potentially revolutionizing mental health disorder treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Nexalin Technology, Inc. receives a new method of use patent for their non-invasive deep brain stimulation device, enabling treatment for anxiety, depression, and insomnia from the comfort of patients' homes. The patent covers the technology utilized in their Gen-3 HALO Clarity™ system, extending through 2040. CEO Mark White highlights the significance of the patent in enhancing the company's strategy and clinical data supporting the device's benefits. The Gen-3 system represents a state-of-the-art development in Nexalin's technology, offering painless neural stimulation for mental health conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Nexalin Technology, Inc. appoints former Acting General Counsel to the Department of Veterans Affairs, William A. Hudson, Jr., to its Military & Government Advisory Board. Hudson's extensive experience in military and government law will aid Nexalin in advancing its non-invasive, deep-brain stimulation devices for mental health conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Nexalin Technology, Inc. announced positive results from a clinical study on its Gen-2 tACS device for treating pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study showed a significant decrease in PCS and PTSD symptoms compared to the control group. The company's strategy aims to provide a non-medication treatment option for mTBI without side effects, supported by VA and UCSD collaboration. The study was a randomized, double-blind trial with promising outcomes, reinforcing Nexalin's commitment to improving mental healthcare outcomes for patients with mTBI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Nexalin Technology, Inc. presented its Gen-3 Halo Clarity device at the 'State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment' hosted by USAMRDC and BARDA. The device aims to treat TBI, PTSD, and other conditions non-invasively. The company received positive feedback from leading experts and government officials, indicating a growing interest in non-drug therapeutic options for TBI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Nexalin Technology, Inc. announced positive results of a clinical study on its Gen-2 tACS device for chronic insomnia treatment. The study showed significant improvements in sleep parameters, with older participants benefiting more. Chronic insomnia affects 6-10% of adults worldwide, and the market for insomnia treatment is valued at over $5 billion. The study results were published in the Journal of Psychiatric Research, highlighting the device's efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) has received regulatory approval from the Sultanate of Oman’s Ministry of Health for its second generation neurostimulation device, marking the company's first regulatory approval outside of China. The CEO, Mark White, expressed excitement about entering the Middle East market and hinted at plans to seek approval in other international markets. The company aims to finalize a commercial distribution agreement in Oman and capitalize on the growing clinical data supporting the benefits of its non-invasive, drug-free device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Nexalin Technology, Inc. announced the award of a U.S. patent for its non-invasive, frequency-based deep brain stimulation device, extending IP protection through 2040. The Gen-3 system is a significant advancement to the predecessor Gen-1 system, providing painless brain neural stimulation for mental health conditions. Clinical studies have demonstrated therapeutic benefits in conditions such as treatment-resistant depression, migraines, anxiety, and insomnia, with potential applications in addiction, substance use disorder, Alzheimer’s, traumatic brain injury, and PTSD. The global mental health market was estimated at $383 billion in 2020 and is projected to reach $537 billion by 2030, indicating significant market potential for Nexalin's neurostimulation device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of Nexalin Technology Warrant (NXLIW)?
The current stock price of Nexalin Technology Warrant (NXLIW) is $0.2011 as of January 6, 2025.
What does Nexalin Technology Inc. offer?
Nexalin provides a drug-free therapy for anxiety, depression, and insomnia using bioelectronic medical technology.
What is the patented waveform technology of the Nexalin device?
The patented waveform provides transcranial electrical stimulation, resulting in increased beta-endorphins and balance in the brain's neurochemistry.
How does the Gen-1 device work?
The Gen-1 device uses bioelectronic medical technology to treat anxiety and insomnia without the need for drugs.
What is the Gen-3 HALO™ Clarity Virtual Clinic model?
The Gen-3 HALO™ Clarity Virtual Clinic model is an innovative approach to providing therapy and support for mental health issues.
Is Nexalin FDA-approved?
Yes, Nexalin has undergone extensive safety analysis and FDA approval for its therapy devices.
What makes Nexalin a leader in mental health treatment?
Nexalin's focus on safe, non-invasive, and effective therapy solutions positions them as leaders in combating the global mental health epidemic.
What clinical data supports Nexalin's therapy?
Growing clinical data supports the efficacy of Nexalin's neurostimulation technology in treating mental health disorders.
How does Nexalin's therapy differ from traditional treatments?
Nexalin's therapy offers a drug-free, non-invasive approach to treating anxiety, depression, and insomnia, without the need for psychotherapy.
Where can I learn more about Nexalin Technology Inc.?
For additional information about Nexalin Technology Inc., visit their official website at https://nexalin.com/.
Nexalin Technology, Inc. Warrant